Sei Investments Co. Grows Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Sei Investments Co. grew its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 43.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 408,043 shares of the company’s stock after buying an additional 124,558 shares during the quarter. Sei Investments Co. owned 0.20% of Cellebrite DI worth $8,989,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quarry LP purchased a new stake in Cellebrite DI during the third quarter worth about $27,000. Advisors Asset Management Inc. grew its holdings in shares of Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares in the last quarter. R Squared Ltd purchased a new stake in Cellebrite DI during the 4th quarter worth approximately $100,000. Polen Capital Management LLC acquired a new stake in Cellebrite DI during the 4th quarter worth approximately $222,000. Finally, Victory Capital Management Inc. purchased a new position in Cellebrite DI in the 4th quarter valued at approximately $234,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Down 0.8 %

Shares of CLBT opened at $19.46 on Monday. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -14.00, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The stock has a 50 day moving average price of $20.85 and a 200 day moving average price of $19.91.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Thursday. Finally, Lake Street Capital boosted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.